Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist-Reference-Cited by-同舟云学术

Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist

Published:2023-07-17 Issue:3 Volume:12 Page:136-146
ISSN:2162-4933
Container-title:Current Dermatology Reports
language:en
Short-container-title:Curr Derm Rep

Author:

Fay Christopher J.^ORCID,Iriarte Christopher^ORCID,Allais Blair S.^ORCID,Pisano Catherine E.^ORCID,Jfri Abdulhadi^ORCID,Larocca Cecilia A.^ORCID,LeBoeuf Nicole R.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13671-023-00395-8.pdf

Reference100 articles.

1. Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol. 2020;11: 574271.

2. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82.

3. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.

4. Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1): e2.

5. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma: U.S. Food & Drug Administration; [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel.